UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 34

Sortiert nach

Previous antimicrobial exposure is associated with drug-resistant urinary tract infections in children

Pediatrics (Evanston), 2010-04, Vol.125 (4), p.664

2010

Link zum Volltext

Verfügbarkeit prüfen

A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia

PloS one, 2019-03, Vol.14 (3), p.e0212837

2019

Link zum Volltext

Verfügbarkeit prüfen

The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2021-02, Vol.27 (2), p.262-270

2021

Link zum Volltext

Verfügbarkeit prüfen

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

The New England journal of medicine, 2022-02, Vol.386 (6), p.509-520

2022

Link zum Volltext

Verfügbarkeit prüfen

Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial

Infectious diseases and therapy, 2023-12, Vol.12 (12), p.2725-2743

2023

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetics of molnupiravir in adults with COVID‐19: Lack of clinically important exposure variation across individuals

CPT: pharmacometrics and systems pharmacology, 2023-12, Vol.12 (12), p.1859-1871

2023

Link zum Volltext

Verfügbarkeit prüfen

Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT)

Microbiology spectrum, 2024-03, Vol.12 (3), p.e0356323-e0356323

2024

Link zum Volltext

Verfügbarkeit prüfen

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

The New England journal of medicine, 2022-02, Vol.386 (6), p.509-520

2022

Link zum Volltext

Verfügbarkeit prüfen

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections

Clinical infectious diseases, 2020-04, Vol.70 (9), p.1799-1808

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection

Antimicrobial agents and chemotherapy, 2016-10, Vol.60 (10), p.6234-6243

2016

Link zum Volltext

Verfügbarkeit prüfen

Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections

Journal of antimicrobial chemotherapy, 2017-09, Vol.72 (9), p.2616-2626

2017

Link zum Volltext

Verfügbarkeit prüfen

A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)

Clinical infectious diseases, 2021-12, Vol.73 (11), p.e4539-e4548

2021

Link zum Volltext

Verfügbarkeit prüfen

Reply to Sfeir

Clinical infectious diseases, 2021-04, Vol.72 (8), p.1485-1486

2021

Link zum Volltext

Verfügbarkeit prüfen

Factors Influencing COVID‐19 Risk: Insights From Molnupiravir Exposure‐Response Modeling of Clinical Outcomes

Clinical pharmacology and therapeutics, 2023-06, Vol.113 (6), p.1337-1345

2023

Link zum Volltext

Verfügbarkeit prüfen

Simplification of Imipenem Dosing by Removal of Weight‐Based Adjustments

Journal of clinical pharmacology, 2019-05, Vol.59 (5), p.646-653

2019

Link zum Volltext

Verfügbarkeit prüfen

Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial

Clinical infectious diseases, 2023-11, Vol.77 (11), p.1521-1530

2023

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics, safety, and tolerability of imipenem/cilastatin/relebactam in children with confirmed or suspected gram-negative bacterial infections: A Phase 1b, open-label, single-dose clinical trial

Journal of clinical pharmacology, 2023-12, Vol.63 (12), p.1387-1397

2023

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial

International journal of antimicrobial agents, 2020-09, Vol.56 (3), p.106084, Article 106084

2020

Link zum Volltext

Verfügbarkeit prüfen

Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections

Antimicrobial agents and chemotherapy, 2020-04, Vol.64 (5)

2020

Link zum Volltext

Verfügbarkeit prüfen

Correction to: Virologic Outcomes with Molnupiravir in Nonhospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial

Infectious diseases and therapy, 2024-04

2024

Link zum Volltext

Verfügbarkeit prüfen

Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial

The Journal of infection, 2023-11, Vol.87 (5), p.392-402

2023

Link zum Volltext

Verfügbarkeit prüfen

1574. Multivariate Regression Analysis to Determine Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Trial

Open forum infectious diseases, 2020-12, Vol.7 (Supplement_1), p.S785-S786

2020

Link zum Volltext

Verfügbarkeit prüfen

1159. Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Pediatric Participants With Confirmed or Suspected Gram-negative Bacterial Infections: A Phase 1b, Open-label, Single-Dose Clinical Trial

Open forum infectious diseases, 2021-12, Vol.8 (Supplement_1), p.S671-S671

2021

Link zum Volltext

Verfügbarkeit prüfen

Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis

Open forum infectious diseases, 2023-06, Vol.10 (6), p.ofad225-ofad225

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(34)

Sprache

Englisch
(34)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Previous antimicrobial exposure is associated with drug-resistant urinary tract infections in children

A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia

The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial

Population pharmacokinetics of molnupiravir in adults with COVID‐19: Lack of clinically important exposure variation across individuals

Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT)

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections

Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection

Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections

A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)

Reply to Sfeir

Factors Influencing COVID‐19 Risk: Insights From Molnupiravir Exposure‐Response Modeling of Clinical Outcomes

Simplification of Imipenem Dosing by Removal of Weight‐Based Adjustments

Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial

Pharmacokinetics, safety, and tolerability of imipenem/cilastatin/relebactam in children with confirmed or suspected gram-negative bacterial infections: A Phase 1b, open-label, single-dose clinical trial

Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial

Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections

Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial

Correction to: Virologic Outcomes with Molnupiravir in Nonhospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial

Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial

1574. Multivariate Regression Analysis to Determine Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Trial

1159. Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Pediatric Participants With Confirmed or Suspected Gram-negative Bacterial Infections: A Phase 1b, Open-label, Single-Dose Clinical Trial

Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis

Suchergebnisse filtern